Topline results from the study are anticipated in the first half of 2027.
Feature|Articles|August 7, 2025
Top 5 benign urology headlines you missed in July 2025
Author(s)Hannah Clarke
Fact checked by: Benjamin P. Saylor, Strategic Content Lead
Take a look through key stories from last month, including regulatory news, trial updates, and other practice-changing advancements.
Advertisement
Advertisement
There was a wealth of important developments across urology in July 2025, with notable advancements in benign conditions such as stress urinary incontinence (SUI) and benign prostatic hyperplasia (BPH).
Related to this article
The 2026 LUGPA Annual Meeting will tackle policy, artificial intelligence, and practice growth, according to Benjamin H. Lowentritt, MD, FACS.
JNJ-6143 demonstrated promising PSA and tumor response rates with an encouraging safety profile in heavily pretreated mCRPC, including across genomic subgroups.
Alberto Briganti, MD, PhD, discusses results from the PROTEUS substudy, evaluating perioperative apalutamide plus ADT vs surgery alone in high-risk localized or locally advanced prostate cancer.
In a POTOMAC subgroup analysis, durvalumab plus BCG reduced the risk of high-risk recurrence or death by 44% vs BCG alone in patients with papillary-only, BCG-naive NMIBC.
Updated CAPItello-281 data showed a clinically meaningful benefit in OS when capivasertib was added to abiraterone and ADT in PTEN-deficient mHSPC.
Andrea Necchi, MD, discusses how results from the CA017-078 trials compares with other perioperative immunotherapy trials in muscle-invasive bladder cancer.
In TALAPRO-3, talazoparib plus enzalutamide improved rPFS vs placebo plus enzalutamide (HR, 0.48; P < .0001) in HRR-mutated mAPMN/S prostate cancer.
Advertisement
Advertisement